Cargando…
Gene Therapy for Hemoglobinopathies
Gene therapy for β-thalassemia and sickle-cell disease is based on transplantation of genetically corrected, autologous hematopoietic stem cells. Preclinical and clinical studies have shown the safety and efficacy of this therapeutic approach, currently based on lentiviral vectors to transfer a β-gl...
Autores principales: | Cavazzana, Marina, Mavilio, Fulvio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196755/ https://www.ncbi.nlm.nih.gov/pubmed/30200783 http://dx.doi.org/10.1089/hum.2018.122 |
Ejemplares similares
-
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene
por: Negre, Olivier, et al.
Publicado: (2016) -
Gene Therapy of the Hemoglobinopathies
por: Kunz, Joachim B., et al.
Publicado: (2020) -
Gene Therapy in Thalassemia and Hemoglobinopathies
por: Breda, Laura, et al.
Publicado: (2009) -
Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials
por: Segura, Eva Eugenie Rose, et al.
Publicado: (2023) -
Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases
por: Poletti, Valentina, et al.
Publicado: (2021)